Candriam Luxembourg S.C.A. boosted its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 16.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,000 shares of the company’s stock after buying an additional 14,000 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 0.22% of Global Blood Therapeutics worth $3,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Global Blood Therapeutics by 30.0% in the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock worth $93,114,000 after buying an additional 785,691 shares during the last quarter. Vanguard Group Inc. increased its position in Global Blood Therapeutics by 15.7% in the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock worth $80,224,000 after buying an additional 397,271 shares during the last quarter. State Street Corp increased its position in Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after buying an additional 1,465,595 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Global Blood Therapeutics in the second quarter worth $26,919,000. Finally, Sectoral Asset Management Inc increased its position in Global Blood Therapeutics by 31.0% in the second quarter. Sectoral Asset Management Inc now owns 452,781 shares of the company’s stock worth $12,384,000 after buying an additional 107,199 shares during the last quarter. 86.76% of the stock is owned by institutional investors and hedge funds.
In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total transaction of $437,500.00. Following the sale, the vice president now directly owns 2,684 shares of the company’s stock, valued at approximately $93,940. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the sale, the insider now directly owns 141,655 shares in the company, valued at $4,249,650. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,500 shares of company stock worth $3,093,350. 5.30% of the stock is owned by company insiders.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same period in the previous year, the firm posted ($0.58) earnings per share. equities research analysts anticipate that Global Blood Therapeutics, Inc. will post -2.53 EPS for the current fiscal year.
A number of research firms have issued reports on GBT. SunTrust Banks, Inc. raised their target price on Global Blood Therapeutics to $67.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. BidaskClub raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 1st. Zacks Investment Research lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Cowen and Company reaffirmed a “buy” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a report on Thursday, November 9th. Finally, Oppenheimer Holdings, Inc. set a $53.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $55.00.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).
Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.